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Abstract
Meta-analysis is an increasingly popular tool for combining multiple genome-wide association studies in a single analysis to
identify associations with small effect sizes. The effect sizes between studies in a meta-analysis may differ and these
differences, or heterogeneity, can be caused by many factors. If heterogeneity is observed in the results of a meta-analysis,
interpreting the cause of heterogeneity is important because the correct interpretation can lead to a better understanding
of the disease and a more effective design of a replication study. However, interpreting heterogeneous results is difficult.
The standard approach of examining the association p-values of the studies does not effectively predict if the effect exists in
each study. In this paper, we propose a framework facilitating the interpretation of the results of a meta-analysis. Our
framework is based on a new statistic representing the posterior probability that the effect exists in each study, which is
estimated utilizing cross-study information. Simulations and application to the real data show that our framework can
effectively segregate the studies predicted to have an effect, the studies predicted to not have an effect, and the ambiguous
studies that are underpowered. In addition to helping interpretation, the new framework also allows us to develop a new
association testing procedure taking into account the existence of effect.
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Introduction
Meta-analysis is a tool for aggregating information from
multiple independent studies [1–3]. In genome-wide association
studies (GWASs) [4], the use of meta-analysis is becoming more
and more popular because one can virtually collect tens of
thousands of individuals that will provide power to identify
associated variants with small effect sizes [5–7]. Several large scale
meta-analyses have been performed for diseases including type 1
diabetes [8], type 2 diabetes [9–11], bipolar disorder [12], Crohns
disease [13], and rheumatoid arthritis [14], and have identified
associations not revealed in the individual studies.
In meta-analyses, the effect size between studies may differ and
this difference, or heterogeneity, can be caused by many factors
[15–18]. If the populations are different between studies, the
genetic factors can cause heterogeneity [19,20]. If the subjects are
from different regions, the environmental factors can cause
heterogeneity [21]. Even if the true effect size is invariant, the
design factors can also cause a phenomenon that looks like
heterogeneity, what is often called the statistical heterogeneity
[22]. If the linkage disequilibrium structures are different between
studies, the collected marker can show heterogeneity [23]. If the
studies use different genotyping platforms, different imputation
accuracies and different genotyping errors can cause heterogeneity
[24].
In current meta-analyses of genome-wide association studies,
heterogeneity is often observed in the results [9–11,13,17].
Interpreting the cause of such heterogeneity is important. If the
heterogeneity is caused by either genetic or environmental factors,
understanding the cause of heterogeneity can help our under-
standing of the disease mechanism. If the heterogeneity is
statistical heterogeneity caused by the design factors, understand-
ing the cause of heterogeneity is crucial in designing a replication
study so that we can eliminate the design factors that can hinder
the revelation of the true effect in the replication study.
However, interpreting heterogeneous results is difficult. One
standard approach is to examine the association p-values of the
studies. The inherent limitation of this approach is that a non-
significant p-value is not evidence of the absence of an effect.
Thus, a p-value does not provide the full information necessary for
the interpretation whether or not there is an effect in the study.
Another standard approach is to plot observed effect sizes and
their confidence intervals of all studies [17,25,26]. This plot can be
overly complicated when the number of studies is large and does
not provide a single estimate that represents the existence of an
effect in each study. The limitation of both approaches is that they
use classical estimates that are calculated using only the data of
each single study. That is, they utilize only within-study
information.
In this paper, we propose a framework facilitating the
interpretation of the results of a meta-analysis. Our framework is
based on a new statistic termed the m-value which is the posterior
probability that the effect exists in each study. Plotting the new
statistic together with p-values in a two-dimensional space helps us
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distinguish between the studies predicted to have an effect, the
studies predicted to not have an effect, and the ambiguous studies
that are underpowered. We name this plot a P-M plot. In this
framework, the outlier studies showing distinct characteristics from
the other studies are easily identified, as we demonstrate using data
from type 2 diabetes and Crohns disease meta-analyses [10,13].
Our new statistic is fundamentally different from traditional
estimates based on the data of single studies. We use all studies
simultaneously to calculate the new statistic based on the
assumption that the effect sizes are similar if the effect exists.
Thus, we utilize cross-study information as well as within-study
information.
In addition to helping interpretation, the new framework allows
us to develop a new association testing procedure which takes into
account the presence or absence of the effect. The new method
called the binary effects model is a weighted sum of z-scores
method [5] assigning a greater weight to the studies predicted to
have an effect and a smaller weight to the studies predicted to not
have an effect. Application to the Crohns disease data [13] shows
that the new method gives more significant p-values than previous
methods at certain loci already identified as associated.
The new method is available at http://genetics.cs.ucla.edu/
meta.
Methods
Binary Effects Assumption
In our framework, we use a simplified model to describe
heterogeneity among the studies which makes two assumptions. The
first assumption is that effect is either present or absent in the studies. This
assumption is different from the traditional assumption assuming
normally distributed effect sizes [27–29]. Our assumption is inspired
by the phenomenon that the effect sizes are sometimes observed to
be much smaller in some studies than in the others. It is reported
that different populations can cause such phenomenon
[19,20,30,31]. For example, the homozygosity for APOE e4 variant
is known to confer fivefold smaller risk of Alzheimer disease in
African Americans than in Asians [19,30]. The HapK haplotype
spanning the LTA4H gene is shown to confer threefold smaller risk
of myocardial infraction in the populations of Europeans decent
than in African Americans [31]. The HNF4A P2 promoter variants
are shown to be associated with type 2 diabetes in Ashkenazi and the
results have been replicated [20]. However, in the same study, the
same variants did not show associations in four different cohorts of
UK population suggesting a heterogeneous effect. Gene-environ-
mental interactions can also cause such phenomenon. If a study
lacks an environmental factor necessary for the interaction, the
observed effect size can be much smaller in that study. It is generally
agreed that the gene-environmental interactions exist in many
diseases such as cardio vascular diseases [32], respiratory diseases
[33], and mental disorders [34].
The second assumption is that if the effect exists, the effect sizes
are similar between studies. We call these two assumptions
together the binary effects assumption. While other types of
heterogeneity structures are possible such as arbitrary effect sizes,
for identifying which studies have an effect and which studies do
not have an effect, we expect that this model will be appropriate.
M-Value
We propose a statistic called the m-value which is the posterior
probability that the effect exists in each study of a meta-analysis.
Suppose that we analyze N studies together in a meta-analysis. Let
Xi (i~1,:::,N) be the observed effect size of study i and let Vi be
the estimated variance of Xi. It is a common practice to consider
Vi the true variance. In the current GWASs, the distribution of Xi
is well approximated by a normal distribution due to the large
sample sizes. Let X~fXig denote the observed data.
If there is no effect in study i,
P(Xijno effect)~N(Xi; 0,Vi)
where N(x; a,b) is the probability density function of a normal
distribution whose mean is a and the variance is b. If there is effect
in study i,
P(Xijeffect)~N(Xi; m,Vi)
where m is the unknown true effect size.
Since we want a posterior probability, the Bayesian framework
is a good fit. We assume that the prior for the effect size is
m*N(0,s2):
A possible choice for s in GWASs is 0.2 for small effect and 0.4 for
large effect [35,36].
Let Ti be a random variable which has a value 1 if study i has
an effect and a value 0 if study i does not have an effect. Let p be
the prior probability that each study will have an effect such that
P(Ti~1)~p, i~1,:::,N:
Then we assume a beta prior on p
p*Beta(a,b):
Through this paper, we use the uniform distribution prior (a~1
and b~1), but other priors can also be chosen.
Let T~(T1,:::,TN ) be the vector indicating the existence of
effect in all studies. T can have 2N different values. Let
U~ft1,:::,t2Ng be the set of those values.
Our goal is to estimate the m-value mi, the posterior probability
that the effect exists in study i. By the Bayes’ theorem,
Author Summary
Genome-wide association studies are an effective means
of identifying genetic variants that are associated with
diseases. Although many associated loci have been
identified, those loci account for only a small fraction of
the genetic contribution to the disease. The remaining
contribution may be accounted by loci with very small
effect sizes, so small that tens of thousands of samples are
needed to identify them. Since it is costly to conduct a
study collecting such a large sample, a practical alternative
is to combine multiple independent studies in a single
analysis called meta-analysis. However, many factors, such
as genetic or environmental factors, can differ between the
studies combined in a meta-analysis. These factors can
cause the effect size of the causal variant to differ between
the studies, a phenomenon called heterogeneity. If
heterogeneity exists in the data of a meta-analysis,
interpreting the meta-analysis results is an important but
difficult task. In this paper, we propose a method that
helps such interpretation, in addition to a new association
testing procedure that is powerful when heterogeneity
exists.
Interpreting Meta-Analyses
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mi~P(Ti~1jX )~ P(X jTi~1)P(Ti~1)
P(XjTi~0)P(Ti~0)zP(XjTi~1)P(Ti~1)
~
P
t[Ui
P(X jT~t)P(T~t)P
t[U P(X jT~t)P(T~t)
ð1Þ
where Ui is a subset of U whose elements’ ith value is 1. Thus, we
only need to know for each t the posterior probability of T ,
g(t)~P(X jT~t)P(T~t)!P(T~tjX ),
consisting of the probability of X given T and the prior probability
of T .
The prior probability of T is
P(T~t)~
ð?
{?
P(T~t)p(p)dp
~
ð?
{?
pjtj(1{p)N{jtjp(p)dp
~
ð?
{?
pjtj(1{p)N{jtj
1
B(a,b)
pa{1(1{p)b{1dp
~
B(jtjza,N{jtjzb)
B(a,b)
where jtj is the number of 1’s in t and B is the beta function.
And the probability of X given T is
P(X jT~t)~
ð?
{?
P
i[t0
N(Xi; 0,Vi) P
i[t1
N(Xi; m,Vi)p(m)dm
~ P
i[t0
N(Xi; 0,Vi)
ð?
{?
P
i[t1
N(Xi; m,Vi)p(m)dm
ð2Þ
where t0 is the indices of 0 in t and t1 is the indices of 1 in t. We
can analytically work on the integration to obtain
ð?
{?
P
i[t1
N(Xi; m,Vi)p(m)dm~C:N( X ; 0, Vzs
2)
where
X~
P
i WiXiP
i Wi
and V~
1P
i Wi
where Wi~V
{1
i is the inverse variance or precision. The
summations are all with respect to i [ t1.
C is a scaling factor such that
C~
1
(
ffiffiffiffiffi
2p
p
)N{1
ffiffiffiffiffiffiffiffiffiffiffiffiffi
Pi WiP
i Wi
s
exp {
1
2
X
i
WiX
2
i {
(
P
i WiXi)
2P
i Wi
 !( )
:
The details of the derivation is in Text S1 in Supporting
Information S1. As a result, we can calculate g(t) for every t
and therefore obtain mi for each study i.
MCMC. The drawback of the exact calculation of m-value is
that we need to iterate over all t which is exponential to N. This is
not problematic in most of the current meta-analyses of GWASs,
but will be problematic in future studies if N increases over several
tens. Therefore, here we propose a simple Markov Chain Monte
Carlo (MCMC) method to estimate m-value.
We propose the following Metropolis-Hastings algorithm [37].
1. Start from a random t.
2. Choose a next t’.
3. If g(t)vg(t’), move to t’. Otherwise, move to t’ with probability
g(t’)=g(t).
4. Repeat from step 2.
The set of moves we use for choosing t’ is
fM1,M2,:::,MNg|fMshuffleg. Mi is a simple flipping move of
Ti between 0 and 1. Mshuffle is a move that shuffles the values of
T . This move is introduced to avoid being stuck on one mode in a
special case that there are two modes which can happen when the
observed direction of the effect is opposite in some studies. At each
step, we randomly choose a move from this set assuming a uniform
distribution. We allow nB burn-in and sample nS times. After
sampling, nS samples gives us an approximation of the distribution
over g(t), which subsequently gives the approximations of m-
values by the formula (1).
Interpretations and predictions. The m-value has a valid
probabilistic interpretation that it is the posterior probability that
the effect exists in each study under our binary effects model. If we
are to choose studies predicted to have an effect and studies
predicted to not have an effect, a threshold is needed. In this
paper, we use the threshold of m-value w0:9 for the former and
m-valuev0:1 for the latter. Although this thresholding is arbitrary,
the actual level of threshold is often not of importance because
outlier studies showing different characteristics from the other
studies usually stand out in the plotting framework described
below.
Relationship to PPA. The m-value is closely related to the
posterior probability of association (PPA) based on the Bayes factor
(BF) [35] in the sense that the presence and absence of effects are
essentially describing the same things as the alternative and null
models in the association testing. There are two fundamental
differences. First, in the usual PPA, the prior probability of
association (p) is given by a point prior which is usually a very
small value in GWAS reflecting the fact that the true associations
are few. In our framework, we focus on interpreting meta-analysis
results after we find associations using meta-analysis. Thus, p
reflects our belief on the effect conditioned on that the associations
are already significant. For this reason, we need not use a very
small value but instead choose to use a distribution prior. Second,
the PPA is calculated for each study separately. However, the m-
value is calculated using all studies simultaneously utilizing cross-
study information. Thus, if the binary effects assumption
approximates the truth, the m-value is more effective in
predicting effects than the PPA or equivalently the BF, as we
show by simulations in Results.
P-M Plot
We propose plotting the studies’ p-values and m-values together
in two dimensions. This plot, which we call the P-M plot, can help
interpreting the results of a meta-analysis. Figure 1 shows that how
to interpret such a plot. The right-most (pink) region is where the
studies are predicted to have an effect. Often, a study can be in this
region even if the p-value is not very significant. The left-most (light-
blue) region is where the studies are predicted to not have an effect.
This suggests that the sample size is large but the observed effect size
is close to zero, suggesting a possibility that there exists no effect in
that study. The middle (green) region is where the prediction is
ambiguous. A study can be in this region because the study is
Interpreting Meta-Analyses
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underpowered due to a small sample size. If the sample size
increases, the study will be drawn to either the left or the right side.
If the binary effects assumption does not hold, a study can sit in
an unexpected region and a careful interpretation is necessary. For
example, if the effects are significant but the effect sizes are in
opposite direction in some studies, the studies can sit in the
unusual top left region. However, such case will be rare and may
be a result of the strand errors.
Binary Effects Model
We propose a new type of random effects model meta-analysis
approach called the binary effects model. If the binary effects
assumption holds, that is, if the effect is either present or absent in
the studies, taking into account this pattern of heterogeneity in the
association testing procedure can increase power compared to the
general RE approach [23]. The binary effects model we propose is
the weighted sum of z-scores method [5] where the m-values are
incorporated into the weights. Intuitively, this is equivalent to
assigning a greater weight to the studies predicted to have an effect
and a smaller weight to the studies predicted to not have an effect.
Let Zi~Xi=
ffiffiffiffiffi
Vi
p
be the z-score of study i. The common form of
the weighted sum of z-scores statistic for the fixed effects model is
SFE~
P ffiffiffiffiffiffi
Wi
p
ZiffiffiffiffiffiffiffiffiffiffiffiffiP
Wi
p :
In many cases, the weight
ffiffiffiffiffiffi
Wi
p
approximates to the formffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Np(1{p)
p
where N is the sample size and p is the minor allele
frequency [23]. When the minor allele frequency is similar
between studies, the weight
ffiffiffiffiffiffi
Wi
p
approximates to the popular
form of
ffiffiffiffi
N
p
[5].
The binary effects model statistic we propose is
SBE~
P
mi
ffiffiffiffiffiffi
Wi
p
ZiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiP
m2i Wi
q :
Our method is an empirical approach that uses mi estimated from
the data as the prior weight for each study. Since the m-value is
estimated using all studies, our approach can be thought of as
gathering information from all studies and distributing back to
each study in the form of weight. We choose this approach
because of its simple formulation.
Since mi is not independent of Zi, the statistic does not follow a
normal distribution. Thus, the p-value is obtained using sampling
which can be inefficient. We use two ideas to expedite the
sampling. First, we propose an importance sampling procedure
which is more efficient than the standard sampling. Second, we use
an efficient approximation of m-value. See Text S2 and S3 in
Supporting Information S1 for details.
Simulation Framework
In order to evaluate our methods, we use the following
simulation approach. Assuming a minor allele frequency, a
relative risk, and the number of individuals of Nz=2 cases and
N{=2 controls, a straightforward simulation approach is to
sample Nz alleles for cases and N{ alleles for controls
according to the expected minor allele frequencies in the cases
and controls respectively [38]. However, since we perform
extensive simulations assuming thousands of individuals, we use
an approximation approach that samples the minor allele count
from a normal distribution and rounds it to the nearest non-
negative integer.
Web Resources
The URL for methods presented herein is as follows:
http://genetics.cs.ucla.edu/meta
Results
Simulation of M-Values
We demonstrate a simple simulation example showing how m-
value behaves depending on the presence and absence of the effect
and the sample size. First, we make the following assumptions
throughout all of the experiments in this paper. We assume that
the minor allele frequency of the collected marker is 0.3. We
assume that the equal number of cases and controls are collected
and refers to the total number of individuals as sample size N. We
also assume a very small disease prevalence when we calculate the
expected minor allele frequencies for cases and controls given a
relative risk c. For the details how the expected values are
calculated, see Han and Eskin [23]. Note that these assumptions
are not critical factors affecting our simulation results. In all
experiments, the random effects model (RE) denotes the RE
method of Han and Eskin [23]. We omit the results of the
conventional RE method [15] because they are highly conserva-
tive [23]. Throughout this paper, we use the following priors for
calculating m-values. We use N(0,0:22) for the prior of the effect
size (m). We use the uniform distribution prior, Beta(1:0,1:0), for
the prior of the existence of effect (p).
In this simulation example, we assume four different types of
studies. The first type is a large study having an effect (N~2000
and c~1:3). The second type is a small study having an effect
(N~100 and c~1:3). The third type is a large study not having an
effect (N~2000 and c~1:0). The fourth type is a small study not
having an effect (N~100 and c~1:0). We generate two studies
per each type, constructing a simulated meta-analysis set of total
eight studies. We accept this simulation set only if none of eight
studies’ p-values exceeds the genome-wide threshold (10{8) but
the meta-analysis p-value calculated by the RE approach exceeds
Figure 1. A figure depicting the interpretations based on a P-M
plot.
doi:10.1371/journal.pgen.1002555.g001
Interpreting Meta-Analyses
PLoS Genetics | www.plosgenetics.org 4 March 2012 | Volume 8 | Issue 3 | e1002555
the genome-wide threshold. Otherwise, we repeat. We construct
1,000 meta-analysis sets.
Given this simulated data, we plot the histogram of m-values for
each type of studies separately in Figure 2. Figure 2A shows that
almost all (99.9%) of large studies with an effect are concentrated
on large m-values (w0:9), showing that the m-values effectively
predict that the effect exists in the studies. Figure 2C shows that a
large amount (78.6%) of large studies without an effect are
concentrated on small m-values (v0:1). Figure 2B and 2D show
that when the sample size is small, m-value tends to the mid-range
regardless of the effect, suggesting that the studies are underpow-
ered to determine the presence of an effect.
Comparison of P-Value, M-Value, and BF
In this experiment, we compare the p-value, m-value, and BF
by measuring how well they predict which studies have an effect
and which studies do not have an effect. We assume a meta-
analysis of 10 studies where the effect is either present (c~1:3) or
not. We randomly pick the number of studies having an effect (NE )
from a uniform distribution ranging from 1 to 9, and randomly
decide which studies have an effect. We randomly pick the sample
size of each study from a uniform distribution between 500 and
2,000. Given the sample sizes and the effect sizes, we generate a
meta-analysis study set. We accept the meta-analysis set only if
none of the studies’ p-values exceeds the genome-wide threshold
Figure 2. Histograms of m-values of different types of studies. We assume four types of studies which is the all four combinations of large
sample (N~2,000) and small sample (N~100), and effect (c~1:3) and no effect (c~1:0). We repeatedly simulate a meta-analysis of eight studies,
two studies per each type, and calculate the m-values of the studies.
doi:10.1371/journal.pgen.1002555.g002
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(10{8) and the meta-analysis p-value exceeds the genome-wide
threshold. We repeat until we construct 1,000 meta-analysis sets.
We examine each of 10,000 studies included in the simulated
1,000 meta-analysis sets. For each study, we calculate the p-value,
m-value, and BF. We use the asymptotic BF of Wakefield [39]
assuming the same prior distribution N(0,0:22) about the effect
size as the m-value. Then we evaluate the performance of each
statistic as follows. To evaluate the performance of m-value, we fix
an arbitrary threshold tm so that we predict the studies having m-
valuewtm to have an effect. Since we know the underlying truth if
the effect exists or not in each study, we can measure what
proportion of the studies actually having an effect is correctly
predicted to have an effect (true prediction rate) and what
proportion of the studies actually not having an effect is incorrectly
predicted to have an effect (false prediction rate). Then we change
the threshold tm to draw a curve between the true prediction rate
and the false prediction rate, which is often called the receiver-
operating-characteristic (ROC) curve. We do the same analysis for
p-value and BF.
Figure 3A shows that m-value is superior to p-value and BF in
predicting the studies having an effect. This is because m-value can
utilize the cross-study information when the binary effects
assumption holds. The performances of p-value and BF are
almost identical.
Next, we evaluate the performance of the statistics in predicting
studies not having an effect. The experiment is exactly the same as
the previous experiment except that, given a threshold tm, we
predict the studies having m-valuevtm to not have an effect. We
similarly draw the ROC curves for the three statistics. True and
false prediction rates are defined similarly for the objective of
predicting the studies not having an effect.
Figure 3B shows that the m-value is even more superior to the
other statistics in this experiment than in the previous experiment.
The p-value shows the most inferior performance. This is expected
because p-value is designed for detecting the presence of an effect
but not for detecting the absence of an effect. That is, a non-
significant p-value is not evidence of the absence of an effect but
can be the result of a small sample size. On the other hand, the BF
testing for the absence of an effect is just the reciprocal of the BF
testing for the presence of an effect. Thus, the same BF can be
used for both purposes. Although the BF performs better than the
p-value, the m-value is even more superior. The relative
performance gain of the m-value compared to the BF is due to
the cross-study information utilized.
P-M Plot: Type 2 Diabetes Data
We apply our P-M plot framework to the real data of the meta-
analysis of type 2 Diabetes (T2D) of Scott et al. [10]. The meta-
analysis consists of three different GWAS investigations, the
Finland-United States Investigation on NIDDM Genetics (FU-
SION) [10], the Diabetes Genetics Initiative (DGI) [11], and the
WTCCC [9,40].
In their analysis, two SNPs are shown to have a heterogeneous
effect, rs8050136 and rs9300039. Ioannidis et al. [17] provide an
insightful explanation about the heterogeneity at rs8050136. The
WTCCC/UKT2D groups identified evidence for T2D and body
mass index (BMI) associations with a set of SNPs including
rs8050136 in the FTO region [40]. On the other hand, in the DGI
study, the SNP rs8050136 was not significant. The explanation
that Ioannidis et al. suggest is that the observed association at
rs8050136 (FTO) may be mediated by its association with obesity.
In fact, DGI is the only study where the BMI is matched between
Figure 3. Comparison of prediction accuracies of p-value, m-value, and BF. We simulate 1,000 meta-analysis of 10 studies with varying
sample sizes where only a subset of the studies have an effect. Given 10,000 studies, we threshold each statistic to predict the studies having an
effect and the studies not having an effect, and vary the threshold to draw the ROC curves. In A, true prediction rate is the proportion of the studies
actually having an effect that are correctly predicted to have an effect and false prediction rate is the proportion of the studies actually not having an
effect that are incorrectly predicted to have an effect. In B, true and false prediction rates are similarly defined but in the direction of predicting
studies not having an effect. For BF, we use the asymptotic BF of Wakefield [39] with prior N(0,s2) where s~0:2.
doi:10.1371/journal.pgen.1002555.g003
Interpreting Meta-Analyses
PLoS Genetics | www.plosgenetics.org 6 March 2012 | Volume 8 | Issue 3 | e1002555
cases and controls, and the T2D association appears to be
mediated through a primary effect on adiposity [11]. Thus,
although the truth is unknown, the explanation of Ioannidis et al. is
reasonable. Compared to rs8050136, the cause of heterogeneity at
rs9300039 is less understood. It is suggested that the heterogeneity
might reflect the different tag polymorphisms used in the studies
[17].
To gain insights on these studies, we apply our P-M plot.
Figure 4A shows the forest plot, the plot showing only the p-values,
and the P-M plot for rs8050136. In the P-M plot, DGI appears to
be well separated from the other two studies, even though its m-
value (m~0:22) is not below the threshold (v0:1). Thus, the P-M
plot visualizes that DGI can have a different characteristic from
the others. Such a separation is not clear in the plot showing only
the p-values. In the plot showing only the p-values, DGI is close to
FUSION since FUSION is also not very significant (p~0:01).
However, the m-value of FUSION is much greater (m~0:79) than
that of DGI. This suggests that the effect is much more likely to
exist in the FUSION study than in the DGI study.
Figure 4B shows the plots for rs9300039. The P-M plot shows a
different pattern from the P-M plot of rs8050136. In this P-M plot,
every study has an m-value greater than 0.5. Thus, no study shows
evidence of no effect. Comparing the plots of rs8050136 and
rs9300039 gives an interesting observation. In the plot showing
only the p-values, both SNPs show a specific pattern of p-values
that a single study is considerably more significant than the other
two. However, despite of this similarity in the pattern of p-values,
the two SNPs’ P-M plots look different enough that can lead us to
different interpretations. This shows that our P-M plot can provide
information that is not apparent in the analysis of only the p-
values.
P-M Plot: Crohns Disease Data
We apply our plotting framework to the data of the recent meta-
analysis of Crohns disease of Franke et al. [13]. This meta-analysis
consists of six different GWAS comprising 6,333 cases and 15,056
controls, and even more samples in the replication stage. In this
study, 39 associated loci are newly identified increasing the
Figure 4. P-M plots of the type 2 diabetes meta-analysis results of Scott et al. [10]. Two associated loci showing high heterogeneity are
plotted. The dashed horizontal line shows the genome-wide significance threshold. The dotted vertical lines show the prediction regions based on m-
value.
doi:10.1371/journal.pgen.1002555.g004
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number of associated loci to 71. We apply our framework to six
loci where a high level of heterogeneity is observed. Han and Eskin
[23] showed that at these six loci, RE gave more significant p-
values than the fixed effects model (FE).
Figure 5 shows the P-M plots of two loci. See Figure S1 for the
plots of all six loci. The names of the studies follow the names used
in Franke et al. [13]. At these two loci, rs3024505 and rs17293632,
the m-value of WTCCC is close to the threshold for predicting no
effect. A possible explanation is that the different marker sets could
have caused the statistical heterogeneity at these loci. WTCCC
[40] used the Affymetrix platform while others used the Illumina
platform. Although we do not further investigate this hypothesis, it
is true that the P-M plots visualize an interesting outlier behavior
of WTCCC at these loci. Such an observation is not clear in both
the forest plot and the plot showing only p-values. In the plot
showing only p-values, studies having non-significant p-values are
all clustered and WTCCC is only one of them. In the forest plot,
WTCCC is not the only study showing a small effect size at both
loci. For example, at rs3024505, NIDDKNJ shows a smaller effect
size than WTCCC. However, the m-value of WTCCC is much
smaller than NIDDKNJ’s because of the large sample size. Such
an interaction between the sample size and the prediction can also
be inferred from the forest plot since the forest plot includes the
confidence interval. However, it is difficult to numerically quantify
the effect of sample size on the prediction by visually examining
the forest plot.
Binary Effects Model: False Positive Rate
We estimate the false positive rate of the new binary effects
model (BE). Assuming the null hypothesis of no association, we
construct 5 studies of sample size 1,000 to build a meta-analysis
set. We calculate the meta-analysis p-value of BE using our
importance sampling procedure with 10,000 samples. We also
calculate the meta-analysis p-values of FE and RE. We build 100
million sets of meta-analysis and estimate the false positive rate as
the proportion of the simulated sets whose p-value exceeds a
threshold. We vary the threshold levels from 0.05 to 10{6.
Table 1 shows that all methods including BE control the false
Figure 5. P-M plots of the Crohns disease meta-analysis results of Franke et al. [13]. Two of six associated loci showing high heterogeneity
are plotted. See Figure S1 for the plots of all six loci. The names of the studies follow Franke et al. [13]. The dashed horizontal line shows the genome-
wide significance threshold. The dotted vertical lines show the prediction regions based on m-value.
doi:10.1371/journal.pgen.1002555.g005
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positive rates accurately, at all threshold levels examined. When
we increase the number of studies from 5 to 10, the results are
essentially the same and the false positive rates are controlled
(Data not shown).
Binary Effects Model: Power
We compare the power of BE to the powers of FE and RE.
Assuming a meta-analysis of five studies of an equal sample size
1,000, we construct 10,000 meta-analysis sets. The power of each
method is estimated as the proportion of the meta-analysis sets
whose meta-analysis p-value calculated by each method exceeds
the genome-wide threshold (10{8).
We measure power in two different situations. First, we assume
a situation that the effect is either present or absent. We decrease
the number of studies having an effect (NE ) from 5 to 2. We
increase the relative risk as NE decreases, using c~1:3,1:37,
1:45,1:6 for NE~5,4,3,2 respectively, in order to show the relative
performance between methods.
Figure 6 shows that except for the case that there is no
heterogeneity (NE~5), BE is the most powerful among all
methods. BE is more powerful than RE, even though both are a
random effects model, possibly because it learns the fact that some
studies do not have an effect from the data. When there is no
heterogeneity (NE~5), FE achieves the highest power and BE
achieves the lowest power.
Second, we assume a classical setting where the effect sizes
follow a normal distribution. Assuming that the mean effect size of
c~1:3, we sample the log of effect size of each study from a
normal distribution having the mean log(c) and the standard
deviation k log(c) where k is the parameter we vary. As k
increases, the heterogeneity increases. We measure the power of
each method varying k from zero to one. Figure 7 shows that in
this situation, BE is generally less powerful than RE. The power
difference between BE and RE is the greatest when the
heterogeneity is small. As the heterogeneity increases, BE shows
a similar power to RE.
Binary Effects Model: Real Data
We apply BE to the real data of Crohns disease of Franke et al.
[13]. Han and Eskin [23] showed that out of 69 associated loci
analyzed, RE gave more significant p-values than FE at six loci
where high level of heterogeneity is observed. We calculate the p-
values at these loci using BE and compare to the p-values of FE
and RE.
Table 2 shows that at all six loci where RE gave more significant
p-values than FE, BE gives even more significant p-values. The
reason why BE gives more significant p-values can be explained by
examining the P-M plots of these loci in Figure 5 and Figure S1.
The P-M plots show that at these loci, some studies show high m-
values and some studies show low m-values, suggesting a bimodal
distribution of effect size. Thus, the situation is very similar to the
Table 1. False positive rate of FE, RE, and BE at increasing
significance thresholds.
Threshold FE RE BE
5.0E-02 4.98E-02 (1.00) 4.98E-02 (1.00) 4.98E-02 (1.00)
1.0E-02 9.95E-03 (0.99) 9.92E-03 (0.99) 9.93E-03 (0.99)
1.0E-03 9.93E-04 (0.99) 9.93E-04 (0.99) 9.92E-04 (0.99)
1.0E-04 9.85E-05 (0.99) 9.87E-05 (0.99) 1.00E-04 (1.00)
1.0E-05 9.68E-06 (0.97) 9.51E-06 (0.95) 9.17E-06 (0.92)
1.0E-06 9.70E-07 (0.97) 1.04E-06 (1.04) 1.01E-06 (1.01)
The values in the parentheses are the ratio between the false positive rate and
the threshold. The estimates are obtained from 100 million null panels
assuming 5 studies of an equal sample size 1,000.
doi:10.1371/journal.pgen.1002555.t001
Figure 6. Power of FE, RE, and BE method when the number of
studies having an effect varies. We assume 5 studies and gradually
decrease the number of studies having an effect from 5 to 2. We
assume an equal sample size of 1,000. We increase the odds ratio as the
number of studies decreases to show the relative performance between
methods. The power is estimated as the proportion of the simulated
10,000 meta-analysis sets whose meta-analysis p-value calculated by
each method exceeds the genome-wide threshold (10{8).
doi:10.1371/journal.pgen.1002555.g006
Figure 7. Power of FE, RE, and BE method when the effect size
varies between studies in the pattern following a normal
distribution. The x-axis denotes heterogeneity k where we simulate
the standard deviation of the effect size (log of relative risk) to be k
times the effect size. We assume the mean relative risk of 1.3 and
assume 5 studies of an equal sample size 1,000. The power is estimated
as the proportion of the simulated 10,000 meta-analysis sets whose
meta-analysis p-value calculated by each method exceeds the genome-
wide threshold (10{8).
doi:10.1371/journal.pgen.1002555.g007
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case that the effect is either present or not, in which case BE
achieves higher power than RE as shown in Figure 6.
Binary Effects Model: Accuracy of Importance Sampling
We measure how accurately the importance sampling
procedure of BE estimates the p-value depending on the number
of samples used. We calculate the BE p-value for the same dataset
in 100 different runs to estimate the variance of the p-value
estimate. Our criterion of interest is the ratio between the
standard deviation of our estimate and the target p-value. For
this, we use the 69 associated loci in the Crohns disease data of
Franke et al. [13] that were previously analyzed in Han and Eskin
[23]. We measure the ratio for each locus and average over all
loci. We do this varying the number of samples from 1,000 to
1,000,000.
Table 3 shows that as the number of samples used for importance
sampling increases, the accuracy increases. The pattern of accuracy
increase is what we would usually expect in a sampling procedure;
standard deviation is decreased approximately by the square root of
the sample size increase. When the number of samples is 1,000, the
ratio is roughly 0.5. A ratio of 0.5 is large, but can be enough for
initial screening if we would apply an adaptive sampling that
samples larger number of samples only for loci that are at least
moderately significant (e.g. pv10{4).
Binary Effects Model: Computational Efficiency
We measure the computational efficiency of the importance
sampling procedure of BE. In our software, we implemented an
adaptive sampling procedure that samples smaller number first
(nsmall~1,000) and then larger number (nlarge~100,000) for the
loci that are at least moderately significant. In the machine
equipped with Intel Xeon 1.68 GHz CPU, when we use 1,000
samples in the importance sampling, calculating BE p-values of
1,000 loci for the meta-analysis of 10 studies takes 100 seconds.
Thus, to calculate BE p-values of one million loci assuming that
1,000 loci among them are moderately significant, it will take
approximately 30 hours which is a feasible amount of time. If the
number of samples is increased to achieve better accuracy, such as
nsmall~10,000 and nlarge~1,000,000, the procedure will still be
efficient if one uses multiple computers or a cluster since the
procedure is parallelizable.
Discussion
We introduce a framework facilitating the interpretation of
meta-analysis results based on a new statistic representing the
posterior probability that the effect exists in each study. Our
framework utilizes cross-study information and is shown to help
interpretations in the simulations and the real data. The new
statistic also allows us to develop a new association testing
procedure called the binary effects model.
In the current meta-analyses of genome-wide association
studies, heterogeneity is often observed and our framework will
be a useful tool for interpreting such results. We expect that our
framework will be even more useful in the future meta-analyses. As
the number of studies in a meta-analysis grows, the chance of
heterogeneity will increase [6]. Also, a meta-analytic approach can
often be applied to a broader area such as to multiple diseases with
similar etiology, in which case the heterogeneity is more likely to
occur. Moreover, the majority of the current meta-analyses only
use the fixed effects model (FE). The use of a random effects model
(RE) approach [23] such as the binary effects model presented
herein will increase the number of identified associations showing
heterogeneity, since an RE approach is more powerful than FE for
detecting associations with heterogeneity.
One limitation of our approach is that although the new statistic
can predict the studies having an effect and the studies not having
an effect, it does not distinguish the true heterogeneity and the
statistical heterogeneity [22]. Discriminating between the two can
be very difficult based on the observed data and might often be
possible only by external data such as the replication studies. In
that sense, our method can help discriminating them because one
can come up with a hypothesis based on m-values that the
heterogeneity is caused by specific design factors and then control
the factors in the replication stage. The heterogeneity will
disappear in the replication stage if it was due to the design factors.
Similarly to other Bayesian approaches [35,36], the prior choice
in our method can have a non-negligible effect on the predictions.
Table 3. Accuracy of importance sampling depending on the
number of samples.
# Samples Stdev./P-value
1,000 0.485
10,000 0.172
100,000 0.057
1,000,000 0.018
For each given number of samples used for the importance sampling, we
measure the variance of the p-value estimate of BE by running the importance
sampling 100 different times for the same dataset. We use the 69 associated loci
from the Crohns disease data of Franke et al. [13]. The ratio between the
standard deviation of the estimate and the target p-value is reported, which is
averaged over 69 loci.
doi:10.1371/journal.pgen.1002555.t003
Table 2. Application of FE, RE, and BE to the Crohns disease meta-analysis results of Franke et al. [13].
SNP Chr. Position FE p-value RE p-value BE p-value I2
rs4656940 1 159,096,892 1.05E-06 6.91E-07 3.99E-07 57.01
rs3024505 1 205,006,527 7.03E-09 5.49E-09 2.73E-09 46.49
rs780093 2 27,596,107 1.12E-04 2.78E-05 6.06E-06 61.85
rs17309827 6 3,378,317 5.62E-06 4.98E-06 3.12E-06 22.98
rs17293632 15 65,229,650 6.17E-13 3.41E-13 2.48E-13 52.11
rs151181 16 28,398,018 3.32E-10 3.08E-10 1.95E-10 35.22
The boldface denotes the top p-value among the three methods. Only six associated loci are presented that were shown to have more significant RE p-values than FE
p-values [23].
doi:10.1371/journal.pgen.1002555.t002
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For the prior of the effect size m*N(0,s2), it is important to set a
reasonable value s based on the prior information about the effect
size. See Stephens and Balding [35] for the general guideline for
this choice. For the prior of the probability that the effect exists
p*Beta(a,b), we used the uniform distribution (a~1,b~1) in this
paper. However, different priors can also be used for different
situations. If one expects that most of the studies have an effect, an
asymmetric prior such as a~1:5,b~1 can be used. If one is
certain that the studies having an effect and the studies not having
an effect are mixed, a bell-shape prior such as a~1:5,b~1:5 can
be used. See Figure S2 for the plots of the possible choices of
priors.
Supporting Information
Figure S1 P-M plots of the Crohns disease meta-analysis results
of Franke et al. [13]. Six loci showing high heterogeneity are
plotted. The names of the studies follow Franke et al. [13]. The
dashed horizontal line shows the genome-wide significance
threshold. The dotted vertical lines show the prediction regions
based on m-value.
(PDF)
Figure S2 Possible choices for the prior of the probability that
the effect exists. We show the uniform distribution prior
(a~1,b~1), an asymmetric prior preferring the situation that all
studies have an effect (a~1:2,b~1), an asymmetric prior
preferring the same situation even stronger (a~1:5,b~1), and a
bell-shape prior preferring the situation that the studies having an
effect and the studies not having an effect are mixed
(a~1:5,b~1:5).
(PDF)
Supporting Information S1 This text file includes supporting
information for three subjects: (Text S1) Details of the analytical
calculation of m-value, (Text S2) P-value estimation using
importance sampling for binary effects model, and (Text S3)
Efficient m-value approximation for binary effects model.
(PDF)
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